TABLE 1.
Participant characteristics at baseline
| Characteristic | N (%) or median (range) |
|---|---|
| Male gender (n, %) | 35 (54) |
| Age, y (median, range) | 56 (31–74) |
| Ethnicity (n, %) | |
| Asian | 49 (75) |
| Caucasian | 7 (11) |
| Other | 9 (14) |
| Serum ALT, IU/mL (median, range) | 24 (8–60) |
| Serum HBsAg level, IU/mL (median, range) | 701 (1.6–19,912) |
| Serum HBsAg level < 100 IU/mL (n, ) | 10 (15) |
| Serum HBsAg level <10 IU/mL (n, %) | 7 (11) |
| NA therapy at baseline (n, %) | |
| Entecavir | 42 (65) |
| Tenofovir | 17 (26) |
| Lamivudine | 3 (4.6) |
| Lamivudine/adefovir | 3 (4.6) |
| HBV genotype (n, %)a | |
| A | 3 (5) |
| B | 28 (43) |
| C | 14 (22) |
| D | 10 (15) |
| E | 1 (2) |
| unknown | 9 (14) |
a
Inferred baseline genotype, based on sequencing of HBV DNA before becoming undetectable or after virological relapse.
Abbreviations: ALT, alanine aminotransferase; NA, nucleot(s)ide analogs.